Evaluation of candidate vaccine approaches for MERS-CoV

Lingshu Wang, Wei Shi, Michael Joyce, Kayvon Modjarrad, Yi Zhang, Kwanyee Leung, Christopher R. Lees, Tongqing Zhou, Hadi M. Yassine, Masaru Kanekiyo, Zhi-Yong Yang, Xuejun Chen, Michelle M. Becker, Megan Culler Freeman, Leatrice Vogel, Joshua C. Johnson, Gene G. Olinger, John Paul Todd, Ulaş Bağcı, Jeffrey Solomon, Daniel J. Mollura, Lisa E. Hensley, Peter B. Jahrling, Mark R. Denison, Srinivas S. Rao, Kanta Subbarao, Peter D. Kwong, John R. Mascola, Wing-Pui Kong, Barney S. GrahamNature Communications 2015 · DOI

TL;DR

This study investigates different vaccine strategies for MERS-CoV, finding that a combination of full-length Spike (S) DNA and S1 subunit protein elicits the most robust neutralizing antibody responses in mice and non-human primates. These antibodies target both the receptor-binding domain (RBD) and other parts of the S protein, offering a broader defense mechanism and protection against MERS-CoV-induced lung disease.

What Problem Does This Paper Address?

The Middle East Respiratory Syndrome Coronavirus (MERS-CoV) emerged in 2012 and has a high fatality rate, creating an urgent need for effective vaccines. Previous vaccine development efforts for MERS-CoV primarily focused on the receptor-binding domain (RBD) of the viral Spike (S) protein, which is responsible for attaching the virus to host cells. However, the authors hypothesize that this narrow focus might not be sufficient to elicit optimal neutralizing antibody (NAb) responses. They aim to explore alternative vaccine approaches, specifically using full-length S protein and its S1 subunit, to generate a more comprehensive immune response that could neutralize the virus through multiple mechanisms and potentially offer better protection.

Methods

The researchers designed and tested five candidate vaccine constructs: three DNA-based (full-length S, transmembrane-deleted S, and S1 subunit) and two protein-based (truncated S with transmembrane domain deleted, and S1 subunit). These were administered to mice using various immunization regimens. To assess immunogenicity, they developed a pseudotyped reporter virus neutralization assay, which allowed them to test neutralization against multiple MERS-CoV strains without requiring a biosafety level 3 facility. They also characterized the specificity of the neutralizing antibodies by using cell adsorption assays and protein competition assays with different Spike protein domains (RBD, S1, S2). To understand the structural basis of neutralization, they solved the atomic structure of a neutralizing antibody (mAb D12) in complex with the MERS-CoV RBD. Additionally, they analyzed neutralization escape mutations and constructed MERS-CoV S variants for serological assays. Finally, the most promising vaccine regimens were tested in rhesus macaques, with protection assessed by computerized tomography (CT) scans to evaluate lung infiltrates after viral challenge.

Datasets

The study utilized MERS-CoV strains, including England1 (GenBank ID: AFY13307), EMC, JordanN3 (GenBank ID: KC776174.1), Buraid1, Bisha1, Batin1, Hasha14b, and Munich. They also used SARS-CoV pseudovirus for negative control experiments. The primary "dataset" for evaluation was the serum samples collected from immunized mice and non-human primates, which were then tested for neutralizing antibody titers and protection against MERS-CoV challenge.

Key Insights and Ideas

  • Beyond the RBD: The study strongly suggests that focusing solely on the RBD for MERS-CoV vaccines might be suboptimal. Their findings indicate that targeting other regions of the Spike protein (S1 and S2 subunits) can elicit neutralizing antibodies with different mechanisms of action, potentially leading to broader and more effective immunity.
  • Multi-mechanism Neutralization: The research demonstrates that a comprehensive immune response can neutralize MERS-CoV through multiple pathways, not just by blocking viral attachment (RBD-mediated). This includes potential inhibition of viral fusion.
  • Structural Basis of Neutralization: Solving the crystal structure of a neutralizing antibody (mAb D12) bound to the RBD provided crucial insights into how antibodies can block viral entry and identified key residues involved in this interaction. This structural information is invaluable for rational vaccine design.
  • DNA Prime-Protein Boost Advantage: The DNA prime followed by S1 protein boost regimen in mice and NHPs showed a more diverse antibody repertoire and a Th1-biased immune response, which is generally associated with better viral control. This suggests that a combined DNA and protein approach might offer superior protection.
  • In Vivo Protection: The study provides compelling evidence of vaccine efficacy in non-human primates, with immunized animals showing significantly reduced lung infiltrates after MERS-CoV challenge, supporting the translation of these findings to human vaccine development.

Key Results

  • Robust NAb Titers: The immunization regimen combining full-length S DNA priming and S1 protein boosting elicited the highest neutralizing antibody (NAb) titers in mice.
  • Broad Neutralization: Sera from immunized mice showed robust NAb titers against multiple MERS-CoV strains, indicating cross-neutralization.
  • Antibody Specificity: Serological analysis revealed that immunization elicits NAbs targeting both the RBD and non-RBD portions of the S1 and S2 subunits.
  • Structural Insights: The atomic structure of mAb D12 complexed with the MERS-CoV RBD elucidated the antibody's binding site and identified critical residues for neutralization.
  • Protection in NHPs: Rhesus macaques immunized with either the S DNA/S1 protein or S1/S1 protein regimens showed significantly reduced pulmonary consolidation (lung infiltrates) after MERS-CoV challenge, as assessed by CT scans. The S DNA/S1 protein group exhibited a lower peak of pulmonary disease and faster clearance of infiltrates.

Limitations and Future Work

  • Animal Model Differences: The authors acknowledge that NHP IC90 neutralization titers were approximately 1 log10 lower than in mice, which could be due to differences in animal models, vaccine doses, or adjuvants used.
  • Clinical Symptoms: No significant differences in clinical symptoms, laboratory test values, or histopathology were observed between vaccinated and unvaccinated NHPs, despite the radiologic protection.
  • Correlation with Protection: There was no statistically significant correlation between neutralization antibody levels and the percentage of abnormal lung volume at the time of challenge or peak response, suggesting that other immune mechanisms might also contribute to protection.
  • Future Work: The study suggests that further optimization of boost intervals and the exploration of other vaccine delivery platforms could enhance immune responses. The structural insights gained are crucial for designing next-generation immunogens that target conserved epitopes and potentially overcome escape mutations. The authors also propose that this iterative cycle of antigen design, antibody discovery, and characterization in animal models can be applied to other emerging viral pathogens.

Summary updated

Abstract

The emergence of Middle East respiratory syndrome coronavirus (MERS-CoV) as a cause of severe respiratory disease highlights the need for effective approaches to CoV vaccine development. Efforts focused solely on the receptor-binding domain (RBD) of the viral Spike (S) glycoprotein may not optimize neutralizing antibody (NAb) responses. Here we show that immunogens based on full-length S DNA and S1 subunit protein elicit robust serum-neutralizing activity against several MERS-CoV strains in mice and non-human primates. Serological analysis and isolation of murine monoclonal antibodies revealed that immunization elicits NAbs to RBD and, non-RBD portions of S1 and S2 subunit. Multiple neutralization mechanisms were demonstrated by solving the atomic structure of a NAb-RBD complex, through sequencing of neutralization escape viruses and by constructing MERS-CoV S variants for serological assays. Immunization of rhesus macaques confers protection against MERS-CoV-induced radiographic pneumonia, as assessed using computerized tomography, supporting this strategy as a promising approach for MERS-CoV vaccine development.
BibTeX
@inproceedings{wang2015evaluation,
  author = {Lingshu Wang and Wei Shi and Michael Joyce and Kayvon Modjarrad and Yi Zhang and Kwanyee Leung and Christopher R. Lees and Tongqing Zhou and Hadi M. Yassine and Masaru Kanekiyo and Zhi-Yong Yang and Xuejun Chen and Michelle M. Becker and Megan Culler Freeman and Leatrice Vogel and Joshua C. Johnson and Gene G. Olinger and John Paul Todd and Ulaş Bağcı and Jeffrey Solomon and Daniel J. Mollura and Lisa E. Hensley and Peter B. Jahrling and Mark R. Denison and Srinivas S. Rao and Kanta Subbarao and Peter D. Kwong and John R. Mascola and Wing-Pui Kong and Barney S. Graham},
  title = {{Evaluation of candidate vaccine approaches for MERS-CoV}},
  booktitle = {Nature Communications},
  year = {2015},
  doi = {10.1038/ncomms8712},
}
Figure